Groupama Asset Managment Grows Holdings in Repligen Co. (NASDAQ:RGEN)

Groupama Asset Managment boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 12,321.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 403,932 shares of the biotechnology company’s stock after purchasing an additional 400,680 shares during the period. Groupama Asset Managment owned approximately 0.72% of Repligen worth $58,142,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of RGEN. Ballentine Partners LLC grew its holdings in shares of Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after buying an additional 72 shares during the last quarter. CIBC Asset Management Inc grew its stake in shares of Repligen by 5.0% in the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after purchasing an additional 81 shares during the last quarter. MML Investors Services LLC increased its holdings in shares of Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 89 shares during the period. GAMMA Investing LLC raised its stake in shares of Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 90 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in shares of Repligen by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock worth $2,087,000 after purchasing an additional 100 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on RGEN shares. Canaccord Genuity Group upped their price objective on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Evercore ISI assumed coverage on Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price target for the company. Finally, Royal Bank of Canada upped their price objective on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Repligen has an average rating of “Hold” and a consensus price target of $178.64.

Repligen Trading Down 4.6 %

NASDAQ:RGEN opened at $127.24 on Tuesday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a fifty day simple moving average of $153.54 and a 200-day simple moving average of $148.08. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $184.98. The company has a market capitalization of $7.14 billion, a PE ratio of -249.49, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. On average, equities research analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.